



For Immediate Release

Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015

SOUTH SAN FRANCISCO, Calif., August 17, 2015 — Vaxart, Inc., a privately held, clinical-stage company developing vaccines that are administered by tablet rather than by injection, today announced that Wendy Peters, PhD, Associate Director of Immunology, will present preclinical data on Vaxart's HSV-2 therapeutic vaccine at the 6th Euro Global Summit and Expo on Vaccines and Vaccination (Euro Vaccines-2015) in Birmingham, UK.

The presentation "A Non-Replicating Ad5 Vaccine for the Treatment of HSV-2 Infection" will take place on Tuesday, August 18, 2015 at 11:10 a.m. Greenwich Mean Time. Euro Vaccines-2015 will be held at the Hilton Birmingham Metropole Hotel National Exhibition Centre.

About Vaxart

Vaxart is a privately held, clinical-stage company developing a broad range of vaccines based on its proprietary oral recombinant vaccines platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, and reduce medical waste and risk of needle-stick injury associated with injectable vaccines. For more information, please visit www.vaxart.com.

###

CONTACT:

Katie Hogan

WCG

415.658.9745

khogan@wcgworld.com